103 related articles for article (PubMed ID: 29630518)
1. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer.
Lu R; Zhang J; Zhang W; Huang Y; Wang N; Zhang Q; Qu S
Cancer Biomark; 2018; 22(2):249-256. PubMed ID: 29630518
[TBL] [Abstract][Full Text] [Related]
2. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
[TBL] [Abstract][Full Text] [Related]
3. Long-Noncoding-RNA HOTAIR Upregulation is Associated with Poor Breast Cancer Outcome: A Systematic Review and Meta Analysis.
Suwardjo S; Gilang Permana K; Aryandono T; Heriyanto DS; Anwar SL
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1169-1182. PubMed ID: 38679975
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of breast cancer recurrence in pathologic complete response achieved by patients following neoadjuvant chemotherapy: a single-center retrospective study.
Choi JY; Woen D; Jang SY; Lee H; Shin DS; Kwak Y; Lee H; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
Front Oncol; 2023; 13():1230310. PubMed ID: 37849818
[TBL] [Abstract][Full Text] [Related]
5. Circulating ESR1, long non-coding RNA HOTAIR and microRNA-130a gene expression as biomarkers for breast cancer stage and metastasis.
Abdel-Hamid NR; Mohammed EA; Toraih EA; Kamel MM; Abdelhafiz AS; Badr FM
Sci Rep; 2023 Dec; 13(1):22654. PubMed ID: 38114755
[TBL] [Abstract][Full Text] [Related]
6. Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy.
Baulies S; Belin L; Mallon P; Senechal C; Pierga JY; Cottu P; Sablin MP; Sastre X; Asselain B; Rouzier R; Reyal F
Br J Cancer; 2015 Jun; 113(1):30-6. PubMed ID: 26079300
[TBL] [Abstract][Full Text] [Related]
7. Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence.
Huang J; Zhang JL; Ang L; Li MC; Zhao M; Wang Y; Wu Q
Front Endocrinol (Lausanne); 2023; 14():1265520. PubMed ID: 37900131
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer.
Anwar SL; Sari DNI; Kartika AI; Fitria MS; Tanjung DS; Rakhmina D; Wardana T; Astuti I; Haryana SM; Aryandono T
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1223-1228. PubMed ID: 31030498
[TBL] [Abstract][Full Text] [Related]
9. Integrated single-cell and bulk RNA sequencing analysis identifies a neoadjuvant chemotherapy-related gene signature for predicting survival and therapy in breast cancer.
Zhang X; Feng R; Guo J; Pan L; Yao Y; Gao J
BMC Med Genomics; 2023 Nov; 16(1):300. PubMed ID: 37996875
[TBL] [Abstract][Full Text] [Related]
10. A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients.
Kim R; Kawai A; Wakisaka M; Funaoka Y; Yasuda N; Hidaka M; Morita Y; Ohtani S; Ito M; Arihiro K
Cancer Immunol Immunother; 2019 Apr; 68(4):577-585. PubMed ID: 30673828
[TBL] [Abstract][Full Text] [Related]
11. A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study.
Wang MD; Duan FF; Hua X; Cao L; Xia W; Chen JY
Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836576
[TBL] [Abstract][Full Text] [Related]
12. Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy.
Xiu Y; Jiang C; Huang Q; Yu X; Qiao K; Wu D; Yang X; Zhang S; Lu X; Huang Y
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16097-16110. PubMed ID: 37698677
[TBL] [Abstract][Full Text] [Related]
13. Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy.
Yin G; Liu L; Yu T; Yu L; Feng M; Zhou C; Wang X; Teng G; Ma Z; Zhou W; Ye C; Zhang J; Ji C; Zhao L; Zhou P; Guo Y; Meng X; Fu Q; Zhang Q; Li L; Zhou F; Zheng C; Xiang Y; Guo M; Wang Y; Wang F; Huang S; Yu Z
Genome Med; 2024 Jan; 16(1):11. PubMed ID: 38217005
[TBL] [Abstract][Full Text] [Related]
14. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer.
Zhou J; Shen J; Seifer BJ; Jiang S; Wang J; Xiong H; Xie L; Wang L; Sui X
Oncotarget; 2017 May; 8(18):30477-30494. PubMed ID: 27802185
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the relationship between Ki67 expression level and neoadjuvant treatment response and prognosis in breast cancer based on the Neo-Bioscore staging system.
Sullu Y; Tomak L; Demirag G; Kuru B; Ozen N; Karagoz F
Discov Oncol; 2023 Oct; 14(1):190. PubMed ID: 37875716
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer.
Wei S; Liu L; Zhang J; Bowers J; Gowda GA; Seeger H; Fehm T; Neubauer HJ; Vogel U; Clare SE; Raftery D
Mol Oncol; 2013 Jun; 7(3):297-307. PubMed ID: 23142658
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Magbanua MJM; Li W; Wolf DM; Yau C; Hirst GL; Swigart LB; Newitt DC; Gibbs J; Delson AL; Kalashnikova E; Aleshin A; Zimmermann B; Chien AJ; Tripathy D; Esserman L; Hylton N; van 't Veer L
NPJ Breast Cancer; 2021 Mar; 7(1):32. PubMed ID: 33767190
[TBL] [Abstract][Full Text] [Related]
18. Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.
Giro C; Yamada AMTD; Cruz FJSM; do R Barros LA; da C A Alves B; Fonseca FLA; Del Giglio A
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38743176
[TBL] [Abstract][Full Text] [Related]
19. The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women.
Elias-Rizk T; El Hajj J; Segal-Bendirdjian E; Hilal G
Sci Rep; 2020 Dec; 10(1):22228. PubMed ID: 33335214
[TBL] [Abstract][Full Text] [Related]
20. Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy.
Li Z; Dai K; Wang C; Song Y; Gu F; Liu F; Fu L
J Cancer; 2016; 7(9):1125-32. PubMed ID: 27326256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
